PPT-CAR-T Therapy in non-Hodgkin lymphomas

Jonathon B Cohen MD Dept of Hematology Medical Oncology CoDirector Lymphoma Program Relapsed aggressive nhl associated with shortened survival Scholar1 Crump et al Blood 2017 Martin et al Blood 2016. 1800 620 420 www.leukaemia.org.au 1800 620 420 info@leukaemia.org.au 1800 620 420 www.leukaemia.org.au 1800 620 420 info@leukaemia.org.au OW GRADE ATCH AND ymphoma (often involving extra-n 1800 620 420 www.leukaemia.org.au 1800 620 420 info@leukaemia.org.au 1800 620 420 www.leukaemia.org.au 1800 620 420 info@leukaemia.org.au OW GRADE ATCH AND ymphoma (often involving extra-n Dr Amin Islam. MB, MRCP UK, FRCPath UK. Consultant Haematologist. SUHFT. www.janaanhealth.org. GP Refresher course. 3. rd. October 2016. Education Centre. Munir Gharaibeh, MD, PhD, MHPE. Department of Pharmacology. Faculty of Medicine. October 2019. Cancer drugs—cell cycle. Anticancer Drugs Targets. Drugs used in Leukemias, Lymphomas. Antitumor antibiotics:. Klinika Hematologii, Nowotworów Krwi i Transplantacji Szpiku. We Wrocławiu. Aleksandra Bogucka-Fedorczuk. Definition . Non-. Hodgkin. lymphoma (NHL) . is. a . heterogenous. . group. of . neoplasm. lecture 3. Lecturer . Dr.Mohanad Al-Hindawi. MBCHB, MSc. Histopathology, . CABHS.Anatomical. pathology. Non-Hodgkin lymphoma-Clinical . features . Two thirds of NHLs and . (virtually all Hodgkin lymphomas) . Non-Hodgkin’s lymphoma (. NHL) is a term covering all . lymphoproliferative. system malignancies except Hodgkin's lymphoma . The disease is rare in subject under 30 years of age and incidence increase with age . Around two-thirds of all cases are diagnosed in people over 60 years . . . Assistant Professor :. Dr.Maysem. . Mouayad. . Alwash. . . . Lymphocytes are the immunologically competent cells that assist the phagocytes in . defence. of the body against infection and other foreign invasion.. How to cite: Kusminsky G, Abriata G, Forman D, Sierra MS (2016).Etiology of Hodgkin lymphoma (C81) in Central and South America.In: Cancer in Central and South America.Lyon: International Agency for L, FILIPPAP, MOWAN. Primary nasal paranasaloropharyngeal lymphoma in the pediatric agegroup. Cancer 1990; 65: 1438-1444.YP, SYW,XF, ZXH, LRadiotherapy As Primary Treatment for stage IEand IIE nasal na lymph nodes . Tonsils and adenoids (Waldeyer's ring) . Peyer's patches and appendix . White pulp of the spleen . Lymphadenopathy :. Localized (e.g., infection) or generalized (Systemic disease). . May be due to inflammatory, reactive or neoplastic disorders. Blood bank rotation presentation. 9/20/18. Outline. Mechanism of CAR T cell therapy. Manufacturing process. Challenges . of expanding CAR T cell therapy to a . larger . patient population. . world-wide. NCCN. Christchurch. Hodgkin Lymphoma. Great success story!. LMIC. >50% 0-10yrs old. Striking male predominance. Symptoms. 60% < 6months. B symptoms 40%. Wt. loss. Fever. Night sweats. Staging. JR2 Medicine. Malignancy of mature B lymphocytes;. Represents ~ 10% of all lymphomas diagnosed each year.. Formerly called Hodgkin's disease.